DelMar Pharmaceuticals (DMPI) Receives Average Recommendation of “Buy” from Brokerages

DelMar Pharmaceuticals (NASDAQ:DMPI) has been assigned a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have given a strong buy rating to the company. DelMar Pharmaceuticals’ rating score has improved by 10.2% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Brokerages have set a twelve-month consensus price objective of $11.16 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 179 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, January 4th.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP purchased a new stake in DelMar Pharmaceuticals (NASDAQ:DMPI) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned 1.69% of DelMar Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 5.50% of the company’s stock.

NASDAQ DMPI remained flat at $$0.92 during trading on Friday. 31,391 shares of the company’s stock were exchanged, compared to its average volume of 592,115. The firm has a market capitalization of $20.55, a PE ratio of -1.24 and a beta of 1.47. DelMar Pharmaceuticals has a 1 year low of $0.78 and a 1 year high of $4.45.

DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its earnings results on Thursday, February 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. equities research analysts anticipate that DelMar Pharmaceuticals will post -0.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “DelMar Pharmaceuticals (DMPI) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3336290/delmar-pharmaceuticals-dmpi-receives-average-recommendation-of-buy-from-brokerages.html.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Alliance Data  Raised to Hold at Zacks Investment Research
Alliance Data Raised to Hold at Zacks Investment Research
Cirrus Logic  Downgraded by Zacks Investment Research
Cirrus Logic Downgraded by Zacks Investment Research
Summer Infant  Upgraded to Hold by Zacks Investment Research
Summer Infant Upgraded to Hold by Zacks Investment Research
QNB  Issues  Earnings Results
QNB Issues Earnings Results
Royal Dutch Shell  Upgraded to “Buy” by Zacks Investment Research
Royal Dutch Shell Upgraded to “Buy” by Zacks Investment Research
HP  Downgraded by Zacks Investment Research to Hold
HP Downgraded by Zacks Investment Research to Hold


© 2006-2018 Ticker Report. Google+.